Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Yan Gao

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

Y. Gao1, Q. Chen2, W. Yue3

Author affiliations

  • 1 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medicial University, 100006 - Beijing/CN
  • 2 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medicial University, 100026 - Beijing/CN
  • 3 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 100026 - Beijing/CN
More

Resources

Abstract 3156

Background

LAPTM5 (lysosomal-associated protein transmembrane 5) is a protein that is preferentially expressed in immune cells, and it interacts with the Nedd4 family of ubiquitin ligases. Recent studies in T and B cells identified LAPTM5 as a negative regulator of T and B cell receptor levels at the plasma membrane, but a positive modulator of inflammatory signaling pathways and hence cytokine secretion in macrophages. However, the expression and function of LAPTM5 in ovarian cancer remains undefined.

Methods

LAPTM5 expression in ovarian cancer, benign and normal ovarian tissues was examined by immunohistochemistry. The LAPTM5 mRNA and protein level of OV cells were detected by Q-PCR and Western blotting respectively. Cell apoptosis, migration and invasion changes were observed through high-content screening. The proteins expression involved in epithelial-mesenchymal transition (EMT) and TGF-β mediated signaling pathways was verified by Werstern blotting and immunofluorescence. The role of LAPTM5 on tumorigenesis in vivo was detected by the xenograft model.

Results

Our study showed that in human OV cell lines and tissues, LAPTM5 were significantly induced at both mRNA and protein levels. Furthermore, an OV cell model with downregulated LAPTM5 were established, revealing a significantly alteration of apoptosis. Moreover, analysis of the changes of migration and invasion, showed significant reduced LAPTM5 suppressed cell metastasis. Proteins involved in EMT were strongly altered, which plays a central role in cell metastasis. In addition, phosphorylated ERK1/2, p38 and JNK, key members of mitogen-activated protein kinase (MAPK) family, and phosphorylated Smad2 and Smad3 of Smad signaling pathways mediated by TGF-β regulating OV cells EMT, were strongly decreased. And, LAPTM5 knockdown also inhibited tumorigenesis in xenograft model.

Conclusions

Taken together, our results suggested that LAPTM 5 acts as a positive modulator of MAPK and TGFβ/Smad signaling pathways mediated by TGFβ in OV cells.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Beijing Obstetrics and Gynecology Hospital, Capital Medical University.

Funding

The National Natural Science Foundation of China (grants 81672838), Beijing Municipal Science & Technology Commission (No. Z181100001718193).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings